Spironolactone and metformin combination therapy as a potential non-hormonal treatment for management of hyperandrogenic symptoms of polycystic ovarian syndrome
Introduction: Polycystic ovarian syndrome (PCOS) is one of the most common endocrinological conditions in women of child-bearing age.1 It is characterised by symptoms of oligo- or anovulation, hyperandrogenism and polycystic ovarian morphology.2 Current mainstay treatment for PCOS involves off-label...
Saved in:
| Main Authors: | Irene Karderinis, Yangxinrui Ma, Telma Viveiros, Neha Deshpande, Bassel Watter, Vikram Talaulikar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Clinical Medicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1470211825001794 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Postmenopausal Hyperandrogenism due to Ovarian Hyperthecosis
by: Laryssa Santos Metzker, et al.
Published: (2023-01-01) -
Correlation of Anti-Müllerian Hormone with Polycystic Ovarian Disease and its Relation with Age
by: Sara Omer Muhammed, et al.
Published: (2019-08-01) -
POLYCYSTIC OVARIAN SYNDROME
by: T. D. Guriev
Published: (2016-08-01) -
Hyperandrogenism-mediated YAP activation drives ovarian inflammation and pyroptosis in PCOS: implications for follicular dysfunction
by: Tianyue Xu, et al.
Published: (2025-07-01) -
ALDOSTERONE ANTAGONISTS. MODERN VIEWS ON THE MECHANISM OF ACTION AND EFFECTS OF SPIRONOLACTONE
by: V. I. Podzolkov, et al.
Published: (2017-05-01)